SRR1315371
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.421
- KRAS_SIGNALING_DN+0.258
- ESTROGEN_RESPONSE_LATE+0.250
- SPERMATOGENESIS+0.215
- OXIDATIVE_PHOSPHORYLATION+0.191
- MYC_TARGETS_V1+0.171
- FATTY_ACID_METABOLISM+0.162
- INFLAMMATORY_RESPONSE+0.149
- BILE_ACID_METABOLISM+0.132
- KRAS_SIGNALING_UP+0.125
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.373
- MITOTIC_SPINDLE-0.343
- MYC_TARGETS_V2-0.317
- DNA_REPAIR-0.290
- NOTCH_SIGNALING-0.277
- G2M_CHECKPOINT-0.276
- E2F_TARGETS-0.264
- TGF_BETA_SIGNALING-0.225
- INTERFERON_ALPHA_RESPONSE-0.219
- INTERFERON_GAMMA_RESPONSE-0.215
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1490524 | GTEX | — | 0.903 |
| 2 | SRR1474466 | GTEX | — | 0.859 |
| 3 | SRR1321046 | GTEX | — | 0.841 |
| 4 | SRR1323764 | GTEX | — | 0.834 |
| 5 | SRR1435293 | GTEX | — | 0.801 |
| 6 | SRR1318426 | GTEX | — | 0.801 |
| 7 | SRR12202468 | — | — | 0.799 |
| 8 | SRR1433750 | GTEX | — | 0.795 |
| 9 | SRR1320892 | GTEX | — | 0.768 |
| 10 | MNG250 | — | — | 0.765 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.421 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.258 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.250 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.215 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.191 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.171 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.162 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.149 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.132 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.125 | Inavolisib | — uncovered |
| MYOGENESIS | 0.103 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.094 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.083 | Inavolisib | — uncovered |
| COMPLEMENT | 0.074 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.068 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.068 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.065 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.038 | Inavolisib | — uncovered |
| COAGULATION | 0.032 | Binimetinib | — uncovered |
| MTORC1_SIGNALING | 0.015 | Inavolisib | — uncovered |